<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818957</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0151</org_study_id>
    <nct_id>NCT04818957</nct_id>
  </id_info>
  <brief_title>Vitamin D Replacement Using Oral Thin Film (OTF) Cholecalciferol in Patients Undergoing Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Vitamin D Replacement Using Oral Thin Film (OTF) Cholecalciferol in Patients Undergoing Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that vitamin D levels can be improved in hematopoietic stem&#xD;
      cell transplantation (HSCT) recipients not responding or tolerating standard enteral&#xD;
      supplementation options by using vitamin D oral thin film (OTF) administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate efficacy of oral thin film (OTF) cholecalciferol&#xD;
      (vitamin D3) replacement in hematopoietic stem cell transplantation (HSCT) recipients who&#xD;
      failed to achieve or sustain adequate vitamin D levels after vitamin D supplementation using&#xD;
      current standard of care, or those unable to take/tolerate currently available enteral&#xD;
      vitamin D formulations. With oral thin film (OTF) cholecalciferol, investigators hope to&#xD;
      significantly improve the ease of administration, restoring compliance and facilitating&#xD;
      therapeutic vitamin D levels without relying on the gut for absorption.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D Level</measure>
    <time_frame>12 weeks from starting vitamin D supplementation</time_frame>
    <description>Number of participants who achieve 25OH vitamin D level &gt;35ng/mL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Hematopoietic Stem Cell Transplantation (HSCT)</condition>
  <arm_group>
    <arm_group_label>Vitamin D Oral Thin Film (OTF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive vitamin D OTF for a maximum of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)</intervention_name>
    <description>Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.</description>
    <arm_group_label>Vitamin D Oral Thin Film (OTF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HSCT recipients of any age with vitamin D levels â‰¤35 ng/mL, or unable to tolerate, or&#xD;
             refractory to enteral supplementation formulations of Vitamin D will be offered&#xD;
             Vitamin D OTF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with 25OHD level &gt;60ng/mL. Subjects can be re-screened multiple times and&#xD;
             enrolled later if they meet study criteria.&#xD;
&#xD;
          -  Subjects with clinically significant and uncontrolled hypercalcemia as deemed by&#xD;
             treating physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison Bartlett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Wallace, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenn Bravo</last_name>
    <phone>(513) 803-4425</phone>
    <email>Jennifer.Bravo@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenn Bravo</last_name>
      <phone>513-803-4425</phone>
      <email>Jennifer.Bravo@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Allison Bartlett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Wallace, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

